Our data also showed that circRNF19A-aa interacts with HNRNPF and recruits HNRNPF to the splice site of AR-V7 to facilitate alternative splicing, which may counteract the antitumor effects of enzalutamide on PCa cells and lead to the CRPC phenotype. Here, AR is linked to posterior cortical atrophy.